surpass 5 tirzepatide Efficacy and safety of in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial Results of SURPASS-1-5 for tirzepatide

As optometrists, we must be mindful of any potential adverse effects our patients medications might have on their overall health and/or on their existing health conditions

1 GLP-1 RA=glucagon-like peptide-1 receptor agonist Victoza efficacy and safety data for patients with type 2 diabetes Interested in CV outcomes for patients also with established cardiovascular disease

Why Analyse the Carnitine & Acylcarnitine Pool

The FTO gene variant (rs9939609) influences not just hunger but also circadian rhythm sensitivity, meaning some patients benefit more dramatically from GLP-1's sleep-regulating effects while others experience a gentler transition

TB-500 partially replicates these effects on the active fragment

Another study of 125,474 people with obesity or who are overweight found that almost 47% of those with Type 2 diabetes and nearly 65% of those without diabetes stopped taking GLP-1s within a year a high rate, said Ezekiel Emanuel, a health services researcher at the University of Pennsylvania and senior author of the study